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Background. Macrophage-mediated renal injury has been
implicated in progressive forms of glomerulonephritis; how-
ever, a role for macrophages in type 2 diabetic nephropathy,
the major cause of end-stage renal failure, has not been estab-
lished. Therefore, we examined whether macrophages may pro-
mote the progression of type 2 diabetic nephropathy in db/db
mice.
Methods. The incidence of renal injury was examined in db/db
mice with varying blood sugar and lipid levels at 8 months of
age. The association of renal injury with the accumulation of
kidney macrophages was analyzed in normal db/+ and diabetic
db/db mice at 2, 4, 6, and 8 months of age.
Results. In db/db mice, albuminuria and increased plasma cre-
atinine correlated with elevated blood glucose and hemoglobin
A1c (HbA1c) levels but not with obesity or hyperlipidemia. Pro-
gressive diabetic nephropathy in db/db mice was associated with
increased kidney macrophages. Macrophage accumulation and
macrophage activation in db/db mice correlated with hyper-
glycemia, HbA1c levels, albuminuria, elevated plasma creati-
nine, glomerular and tubular damage, renal fibrosis, and kidney
expression of macrophage chemokines [monocyte chemoat-
tractant protein-1 (MCP-1), osteopontin, migration inhibitory
factor (MIF), monocyte-colony-stimulating factor (M-CSF)].
The accrual and activation of glomerular macrophages also cor-
related with increased glomerular IgG and C3 deposition, which
was itself dependent on hyperglycemia.
Conclusion. Kidney macrophage accumulation is associated
with the progression of type 2 diabetic nephropathy in db/db
mice. Macrophage accumulation and activation in diabetic
db/db kidneys is associated with prolonged hyperglycemia,
glomerular immune complex deposition, and increased kid-
ney chemokine production, and raises the possibility of specific
therapies for targeting macrophage-mediated injury in diabetic
nephropathy.
Key words: db/db mice, chemokines, immune complex, glomerular in-
jury, tubular injury, renal fibrosis.
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Diabetic nephropathy is the major cause of end-stage
renal failure worldwide, with most cases due to the
growing incidence of type 2 diabetes [1]. Current treat-
ments, involving glycemic and blood pressure control, can
slow the development of diabetic nephropathy, but do
not stop the progression to end-stage renal failure [1,
2]. Therefore, it is important to identify new strategies
and additional therapeutic targets for treating diabetic
nephropathy.
Diabetic nephropathy is generally considered a non-
immune disease; however, examination of human biop-
sies and animal models has shown the presence of
macrophages in diabetic kidneys [3–8]. Macrophages are
known to cause renal injury in experimental models
of immune-mediated kidney disease and they correlate
with renal impairment in human glomerulonephritis [9],
but their role in diabetic nephropathy is poorly under-
stood. It is unclear whether increased numbers of kidney
macrophages in type 2 diabetes is simply a response to
obesity per se, which itself can induce macrophage ac-
crual [10, 11], or if hyperglycemia is the key factor driv-
ing macrophage accumulation. Furthermore, we do not
know whether kidney macrophages correlate with renal
impairment in type 2 diabetes and what mechanisms are
involved in their accumulation.
In the current study, we address these questions in the
db/db mouse model in which all mice become obese, but
only a portion develop hyperglycemia. Because db/db
mice have many similarities to the human disease [12],
the findings of this study are likely to be important in
understanding the role of macrophages in human type 2
diabetic nephropathy.
METHODS
Animal model
Type 2 diabetic mice (db/db) and normal heterozy-
gote controls (db/+) were created from breeding pairs of
C57BL/6 db/+ mice obtained from Jackson Laboratories
(Bar Harbor, ME, USA) and identified by polymerase
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chain reaction (PCR) tissue type analysis for the leptin
receptor. No phenotypic differences were found between
age-matched db/+ and C57BL/6 mice, which are homozy-
gous (+/+) for the leptin receptor. Mice were maintained
on a normal diet under standard animal house condi-
tions and were examined for diabetes from 2 months
of age. Mice were assessed every month for blood glu-
cose (glucometer) and every 2 months for albuminuria.
Hemoglobin A1c (HbA1c) (a marker of protein glyca-
tion) was determined from cardiac blood when animals
were killed. An initial study (experiment 1) was per-
formed on a group of 15 male and 12 female db/db
mice, which were examined for the incidence of obe-
sity, hyperlipidemia, hyperglycemia, and renal injury (al-
buminuria, increased plasma creatinine) and killed at
8 months of age. In a follow-up study (experiment 2),
groups of male diabetic db/db mice (N = 7 to 10) and
nondiabetic db/+ mice (N = 5 to 10) were killed at 2,
4, 6, or 8 months of age to evaluate kidney macrophage
accumulation in relation to the progression of diabetic
nephropathy.
Biochemical analysis
Urine was collected from mice housed in metabolic
cages for 18 hours. Whole blood was collected in the pres-
ence of heparin via cardiac puncture of anesthetized mice.
Triglycerides, cholesterol, HbA1c levels, urine creatinine,
and plasma creatinine were analyzed by the Department
of Biochemistry at the Monash Medical Centre. Urine
albumin was measure by enzyme-linked immunosorbent
assay (ELISA) kit (Bethyl Laboratories, Montgomery,
TX, USA).
Antibodies
Antibodies used in this study were rat antimouse
CD45 (M1/9.3.4); rat antimouse CD68 (FA-11) (Serotec,
Oxford, UK); rat antimouse CD4 (GK1.5); rat antimouse
CD8 (YTS169.4); goat antimouse collagen IV (Santa
Cruz Biotechnologies, Santa Cruz, CA, USA); rabbit
anti-inducible nitric oxide synthase (iNOS) (Santa Cruz
Biotechnologies); fluorescein-conjugated antiprolif-
erating cell nuclear antigen (PCNA) (19A4) (Roche
Biochemicals, Mannheim, Germany); antiactivated
caspase-3 (Asp175) (Cell Signaling Technology, Bev-
erly, MA, USA); fluorescein isothiocyanate (FITC)-
conjugated sheep antimouse IgG F(ab)2 fragments
(Silenus, Melbourne, Australia); and FITC-conjugated
goat antimouse C3 F(ab)2 fragments (ICN Pharmaceu-
ticals, Aurora, Ohio, USA). Isotype-matched irrelevant
IgGs were used as negative controls. Antibodies not
purchased from commercial sources were produced by
cell culture of hybridomas obtained from the American
Tissue Culture Collection (ATCC) (Manassas, VA,
USA).
Renal pathology
Formalin-fixed kidney sections (2 lm) were stained
with periodic acid-Schiff (PAS) reagent to identify kid-
ney structure and hematoxylin to distinguish cell nuclei.
Digital images of glomeruli and interstitial areas were
obtained from microscopy (magnification × 400).
Glomerular cellularity was determined by counting the
number of nuclei in 20 hilar glomerular tuft cross-sections
(gcs) per animal. Glomerular volume was assessed by
measuring the glomerular tuft area with computer image
analysis. The mesangial matrix fraction was determined
from the percentage area of PAS-stained material within
the glomerular tuft. The percentage of atrophic tubules
(dilatation, cell loss, necrosis) was assessed by scoring
400 renal cortical tubules per kidney in randomly selected
microscopic fields. Interstitial volume was determined by
point counting of at least 30% of the renal cortex area.
All scoring was performed on blinded slides.
Probes
cDNA fragments of rat monocyte-colony-stimulating
factor (M-CSF) (758 bp), rat migration inhibitory factor
(MIF) (441 bp), rat monocyte chemoattractant protein-
1 (MCP-1) (407 bp), and rat osteopontin (1083 bp)
were amplified by reverse transcription (RT)-PCR and
cloned into the pMOSBlue vector (Amersham Phar-
macia Biotech, Sydney, Australia). Sense and antisense
riboprobes for M-CSF, MIF, MCP-1, and osteopontin
were labeled with digoxigenin (DIG)-uridine triphos-
phate (UTP) using a T7 RNA polymerase kit (Roche
Biochemicals).
In situ hybridization
In situ hybridization to detect MCP-1, osteopontin,
M-CSF, and MIF were performed on tissue sections
fixed in 10% formalin or 2% paraformaldehyde-lysine-
periodate (PLP) using DIG-labeled sense or antisense
cRNA probes as previously described [11]. The hy-
bridized probe was detected using alkaline phosphatase-
conjugated sheep anti-DIG IgG and color development
with NBT/BCIP (Roche Biochemicals).
Kidney deposition of IgG and C3
IgG and C3 deposits in the kidney were assessed in
4 lm snap-frozen tissue sections fixed in 100% ethanol
for 10 minutes at 4◦C. Tissue sections were rehydrated
in phosphate-buffered saline (PBS) and incubated in
20% normal sheep serum for 30 minutes, followed
by fluorescein-conjugated antibodies detecting mouse
IgG (1:200) or C3 (1:50) for 30 minutes, washing, and
mounting in antifade medium containing 5% DABCO
(1,4-diazabicyclo[2.2.2] octane) (Sigma Chemical Co.,
St. Louis, MO, USA) and 70% glycerin in PBS (pH 8.5).
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Immunofluorescence was assessed in 20 glomerular cross-
sections per animal by semiquantitative scoring (0 to 5)
of the area of glomerular tuft stained: 0 = <1%, 1 = 1%
to 10%, 2 = 10% to 25%, 3 = 25% to 50%, 4 = 50% to
75%, and 5 = 75% to 100%.
Immunohistochemistry staining
Immunoperoxidase staining for leukocytes (CD45,
CD68, CD4, and CD8), macrophage proliferation
(CD68/PCNA), macrophages expressing iNOS
(CD68/iNOS), and collagen IV were performed on
PLP-fixed kidney cryostat sections (5 lm). Immunos-
taining for apoptotic cells (activated caspase-3) were
performed on formalin-fixed kidney paraffin sections
(4 lm) [13]. Tissue sections were incubated for 20 min-
utes with 0.6% hydrogen peroxide followed by avidin
and biotin block (Vector Laboratories, Burlingame,
CA, USA) and 20% normal sheep serum to prevent
nonspecific detection. Sections were then incubated
overnight at 4◦C with 5lg/mL of primary antibody in
1% bovine serum albumin (BSA). After washing in
PBS, sections were incubated with biotinylated goat
antibodies (antirat IgG, antimouse IgG or antirabbit
IgG, 1:200) (Vector Laboratories) or biotinylated rabbit
antibody (antigoat IgG, 1:200 Zymed, San Francisco,
CA, USA) for 1 hour followed by ABC solution (ABC
Kit) (Vector Laboratories) for 1 hour and developed
with 3,3-diaminobenzidine (DAB) (Sigma Chemical Co.)
to produce a brown color. For evaluating macrophages
expressing PCNA or iNOS, tissue sections that were
immunostained for CD68 were microwave-treated at
800W for 12 minutes in 10 mmol/L sodium citrate
(pH 6) to retrieve nuclear antigens, prevent antibody
cross-reactivity and inactivate endogenous alkaline
phosphatase [14]. Following microwave treatment,
sections were maintained at 4◦C during incubations with
20% normal sheep serum/5% BSA (20 minutes) and
then either fluorescein-conjugated anti-PCNA mono-
clonal antibodies (1:100) (Roche Biochemical) or rabbit
anti-iNOS (1:100) (Santa Cruz Biotechnologies). After
washing, sections were incubated at room temperature
for 1 hour with alkaline phosphatase-conjugated sheep
antibodies recognizing either fluorescein (1:300) (Roche
Biochemical) or rabbit IgG (1:50) (Dako, Carpinteria,
CA, USA) and developed with Fast Blue BB salt (Sigma
Chemical Co.).
Quantitation of immunohistochemistry and
in situ hybridization
Immunostained glomerular cells (leukocytes, PCNA,
and iNOS) and glomerular cells expressing mRNA for
chemokines (MCP-1, osteopontin, MIF, and M-CSF)
were counted under high power (×400) in 20 hilar
glomerular tuft cross-sections per animal. Immunos-
Table 1. Characteristics of diabetic and nondiabetic db/db mice at
8 months (experiment 1)
Total Diabetic Nondiabetic
Animals number 27 8 19
Blood glucose mmol/L 14.4 ± 10.2 28.8 ± 5.8a 8.3 ± 2.5
(4.5–33) (16–33) (4.5–13.3)
Hemoglobin A1c % 5.7 ± 2.4 8.6 ± 2.5a 4.4 ± 0.8
(3.0–11.6) (4.7–11.6) (3.0–5.6)
Cholesterol mmol/L 4.6 ± 2.7 2.4 ± 0.7b 5.6 ± 2.6
(1.8–12.5) (1.8–3.3) (3.4–12.5)
Triglycerides mmol/L 1.6 ± 1.6 2.8 ± 2.5b 1.1 ± 0.6
(0.4–7.9) (0.6–7.9) (0.4–2.7)
Body Weight g 55.3 ± 11.4 40.7 ± 9.5a 61.4 ± 4.1
(31.3–70.6) (31.3–58.4) (55.5–70.6)
Data are mean ± SD (range).
aP < 0.0005 vs. nondiabetic; bP < 0.01 vs. nondiabetic.
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Fig. 1. Blood glucose and haemoglobin A1c (HbA1c) levels correlate
with renal injury in db/db mice. A group of 15 male and 12 female db/db
mice were assessed at 8 months of age for albuminuria, blood glucose,
and HbA1clevels. Albuminuria was found to correlate with (A) blood
glucose and (B) HbA1c levels. r = Pearson’s coefficient.
tained interstitial cells (leukocytes and iNOS) were
counted in 25 consecutive high power (×400) intersti-
tial fields (representing 30% to 40% of kidney cortex in
the cross-section) by means of a 0.02 mm2 graticule fit-
ted in the eyepiece of the microscope and expressed as
cells/mm2. Expression of collagen IV was assessed as per-
cent area stained within the glomerular tuft and cortical
interstitium by computer image analysis. Tubular apopto-
sis was determined by counting the percentage of cortical
tubules with cells expressing activated caspase-3 in 1000
tubular cross-sections (tcs) per animal. The percentage
of tubules expressing mRNA for chemokines (MCP-1,
osteopontin, MIF, and M-CSF) was assessed by scor-
ing 400 renal cortical tubules per kidney cross-section
in randomly selected microscopic fields. All scoring was
performed on blinded slides.
Statistical analysis
Statistical differences between two groups were ana-
lyzed by the unpaired Student t test (parametric data) or
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Table 2. Characteristics of normal db/+ and diabetic db/db mice with aging (experiment 2)
db/+ db/db
Age months 2 4 6 8 2 4 6 8
Animals number 5 10 10 9 7 7 9 7
Blood glucose mmol/L 6.1 ± 0.9 6.8 ± 0.6 6.9 ± 0.8 6.3 ± 1.0 11.7 ± 3.7a 18.5 ± 9.9b 19.8 ± 10a 28.9 ± 6.2c
Hemoglobin A1c % 2.9 ± 0.7 2.6 ± 0.4 2.9 ± 0.3 2.9 ± 0.3 7.0 ± 1.2c 6.7 ± 0.9c 7.4 ± 2.0c 9.1 ± 2.1c
Cholesterol mmol/L 3.0 ± 0.7 3.1 ± 0.6 2.9 ± 0.7 2.8 ± 1.0 3.0 ± 0.7 2.5 ± 0.6 4.0 ± 1.5 2.4 ± 0.7
Triglycerides mmol/L 1.1 ± 0.4 1.1 ± 0.4 1.3 ± 0.5 1.1 ± 0.2 1.0 ± 0.2 0.7 ± 0.1 1.3 ± 0.8 3.1 ± 2.5
Body weight g 25.5 ± 1.2 34.9 ± 2.4 34 ± 3.6 37.5 ± 2.9 36.7 ± 2.6c 49.0 ± 4.8c 50.7 ± 7.8c 42.0 ± 9.5
Data are mean ± SD.
aP < 0.01; bP < 0.05; cP < 0.0005 vs. normal db/+ mice.
the Mann Whitney U test (nonparametric data), and dif-
ferences between multiple groups of data were assessed
by one-way analysis of variance (ANOVA) with Bon-
ferroni’s multiple comparison test. Correlation analyses
were performed using Pearson’s coefficient (parametric
data) or Spearman’s coefficient (nonparametric data).
Data were recorded as the mean ± SD and values of
P < 0.05 were considered significant. All analyses were
accomplished using the software in GraphPad Prism 3.0
(GraphPad Software, San Diego, CA, USA).
RESULTS
Incidence of type 2 diabetes and renal injury
in db/db mice (experiment 1)
By 2 months of age, all db/db mice became obese with
a 50% increase in body weight (37 ± 2 g) compared to
the lean db/+ control mice (24 ± 2 g). At 4 months, db/db
mice displayed blood glucose levels ranging from normal
to hyperglycemic (6 to 33 mmol/L). Of these animals, 47%
of male (7/15) and 8% of female db/db (1/12) mice went
on to develop overt diabetes (blood glucose ≥16 mmol/L
at 8 months) (Table 1). Examination of db/db mice at
8 months demonstrated significant correlations between
blood glucose levels and renal injury [albuminuria, r =
0.57; P = 0.002 (Fig. 1A); plasma creatinine, r = 0.39, P =
0.04]; and between HbA1c levels and renal injury [albu-
minuria, r = 0.55, P = 0.003 (Fig. 1B); plasma creatinine,
r = 0.42, P = 0.03]. In comparison, blood triglyceride
levels were elevated in most (5/8) diabetic db/db mice
(Table 1) but showed no correlation with renal injury (al-
buminuria, r = 0.35, P = 0.07; plasma creatinine, r = 0.26,
P = 0.19). In contrast, cholesterol levels were elevated in
nondiabetic db/db mice compared to diabetic db/db mice
(Table 1), showing a correlation with body weight (r =
0.50, P = 0.0078) and an inverse correlation with hy-
perglycemia (r = −0.61, P = 0.0008). Furthermore,
cholesterol levels did not correlate with renal injury (al-
buminuria, r = −0.37, P = 0.06; plasma creatinine, r =
−0.17, P = 0.41). Most diabetic db/db mice showed ei-
ther no gain or a loss of body weight between 6 and
8 months, which resulted in an inverse correlation be-
tween body weight and albuminuria (r = −0.55, P =
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Fig. 2. Kidney macrophage accumulation in db/db and db/+ mice.
Immunostaining analysis identified increases in (A) glomerular
macrophages and (B) interstitial macrophages during the progression
of type 2 diabetes in db/db mice. In comparison, age-matched, normal
db/+ control mice have no significant increase in glomerular or inter-
stitial macrophages. Data = mean ± SD. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P <
0.0005.
0.002), but no correlation between body weight and
plasma creatinine (r = 0.32, P = 0.10).
Kidney macrophage accumulation is associated with
hyperglycaemia in diabetic mice (experiment 2)
Following the onset of diabetes in male db/db mice,
there was a progressive increase in blood glucose and
HbA1c levels between 2 and 8 months of age, which was
significantly greater than normal male db/+ mice at all
time points (Table 2). Similarly, a progressive increase in
kidney leukocytes was identified in diabetic male db/db
mice, which was not seen in normal db/+ controls (Fig. 2).
Comparison of total kidney leukocytes (CD45+) with
the numbers of macrophages (CD68+) and T cells
(CD4+, CD8+) at 8 months of age indicated that almost
all glomerular leukocytes (CD45, 11.0 ± 4.3 cells/gcs;
CD68, 10.0 ± 4.4 cell/gcs; CD4, 0.19 ± 0.08 cells/gcs; CD8,
0.014 ± 0.006 cells/gcs) and interstitial leukocytes (CD45,
350 ± 66 cells/mm2; CD68, 330 ± 65 cells/mm2; CD4,
8.9 ± 0.9 cells/mm2; CD8, 1.4 ± 0.5 cells/mm2) in diabetic
db/db kidneys were macrophages. During the progression
of diabetes, increased numbers of kidney macrophages
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Table 3. Correlation of body characteristics with kidney macrophages in normal db/+ and diabetic db/db mice
Glomerular macrophages Interstitial macrophages
db/+ db/db db/+ db/db
Blood glucose −0.27 (NS) 0.52 (0.0032) −0.42 (0.013) 0.48 (0.0067)
Hemoglobin A1c 0.059 (NS) 0.55 (0.0019) −0.068 (NS) 0.38 (0.041)
Triglycerides −0.15 (NS) 0.27 (NS) −0.17 (NS) 0.23 (NS)
Cholesterol 0.14 (NS) −0.31 (NS) −0.022 (NS) −0.29 (NS)
Body weight 0.39 (0.027) −0.18 (NS) −0.19 (NS) −0.22 (NS)
Analysis was performed on combined groups of either db/+or db/db mice from 2, 4, 6 and 8 months.
Data are r value based on Pearson’s correlation coefficient; (P value); NS is not significant.
Table 4. Renal analysis of normal db/+ and diabetic db/db mice
db/+ db/db
Age months 2 4 6 8 2 4 6 8
Animals number 5 10 10 9 7 7 9 7
Renal dysfunction
Urine mL 0.4 ± 0.1 1.4 ± 0.5 1.0 ± 0.3 1.3 ± 0.6 0.7 ± 0.5 1.6 ± 0.7 2.1 ± 0.8a 3.9 ± 1.2a
Albuminuria ng/18 hours 3.9 ± 1.6 15.3 ± 6.7 6.4 ± 4.8 8.0 ± 3.7 31 ± 19b 31 ± 15b 33 ± 16a 87 ± 74b
Plasma creatinine lmol/L 33 ± 4 33 ± 7 36 ± 10 30 ± 7 31 ± 8 29 ± 9 35 ± 7 63 ± 63b
Glomerular
Volume lm3×104 26.5 ± 5.2 33.0 ± 6.3 24.1 ± 4.9 26.1 ± 6.7 26.3 ± 5.0 25.1 ± 3.9 40.8 ± 7.7c 47.9 ± 7.8c
Cellularity cells/gcs 35.9 ± 2.3 30.6 ± 4.4 31.8 ± 3.7 36.5 ± 2.3 31.3 ± 3.2 32.8 ± 4.1 44.8 ± 4.1c 53.1 ± 4.4c
IgG deposits (0–5) 1.2 ± 0.4 1.6 ± 0.5 1.8 ± 0.4 1.8 ± 0.4 1.7 ± 0.5 2.3 ± 0.5b 3.2 ± 0.8c 4.4 ± 0.5c
C3 deposits (0–5) 0.2 ± 0.5 0.7 ± 0.5 0.9 ± 0.6 1.0 ± 0.0 0.6 ± 0.5 1.4 ± 0.5b 1.7 ± 0.5c 2.9 ± 0.7c
Matrix fraction % 26.8 ± 2.0 27.0 ± 1.2 27.2 ± 1.2 29.3 ± 2.9 30.6 ± 4.1 33.2 ± 0.8a 43.7 ± 4.0c 46.6 ± 4.4c
Collagen IV % area 19.1 ± 0.7 19.5 ± 1.0 18.3 ± 0.9 18.7 ± 1.3 20.4 ± 0.1 21.2 ± 1.5a 23.8 ± 1.8c 27.8 ± 0.7c
Tubules
Atrophic % 0.16 ± 0.06 0.16 ± 0.06 0.17 ± 0.07 0.17 ± 0.04 0.28 ± 0.14 0.39 ± 0.39 1.0 ± 0.69a 3.3 ± 1.3a
Apoptotic % 0.11 ± 0.1 0.07 ± 0.09 0.13 ± 0.13 0.10 ± 0.13 0.15 ± 0.12 0.30 ± 0.26 0.30 ± 0.30 0.74 ± 0.5b
Interstitial
Volume% 1.6 ± 0.5 1.8 ± 0.7 1.6 ± 0.5 2.6 ± 1.3 3.1 ± 0.5a 3.4 ± 0.8c 3.9 ± 0.5c 6.0 ± 0.3c
Collagen IV% area 18.3 ± 1.6 19.0 ± 1.0 19.5 ± 0.9 20.5 ± 1.1 18.8 ± 1.7 19.3 ± 1.4 21.3 ± 1.7a 24.7 ± 2.3c
Macrophages (MØ)
MØ/gcs 0.53 ± 0.33 0.88 ± 0.16 0.78 ± 0.44 1.5 ± 0.8 0.73 ± 0.24 1.8 ± 1.0 2.7 ± 1.3a 10.0 ± 4.4a
% iNOS+ glom MØ 6.2 ± 8.5 5.3 ± 3.2 6.5 ± 6.6 5.2 ± 4.8 21 ± 13 20 ± 6c 20 ± 11b 16 ± 14
% PCNA+ glom MØ 2.9 ± 6.0 ND ND 4.6 ± 5.8 7.9 ± 6.0 ND ND 10 ± 15
int MØ/mm3 160 ± 116 107 ± 36 103 ± 13 129 ± 69 138 ± 58 153 ± 94 163 ± 41a 330 ± 141a
% iNOS+ int MØ 1.2 ± 1.1 2.1 ± 3.4 2.3 ± 2.3 2.1 ± 2.4 2.3 ± 1.9 5.3 ± 4.1 4.6 ± 1.9b 4.8 ± 3.9
% PCNA+ int MØ 0.13 ± 0.35 ND ND 0.39 ± 0.91 0.62 ± 0.9 ND ND 0.91 ± 1.0
Abbreviations are: MØ, macrophage; gcs, glomerular cross-section; iNOS, inducible nitric oxide synthase; glom, glomerular; int, interstitial; PCNA, proliferating cell
nuclear antigen; ND, not determined.
Data are mean ± SD.
aP < 0.01; bP < 0.05; cP < 0.0005 vs. normal db/+ mice.
first appeared in glomeruli at 4 to 6 months and then
later at 6 to 8 months in the interstitium (Fig. 2). At
8 months, there was approximately a sevenfold increase
in glomerular macrophages and a threefold increase in in-
terstitial macrophages in diabetic db/db mice compared
to db+ controls. In diabetic db/db mice, both glomerular
and interstitial macrophages correlated with blood glu-
cose and HbA1c levels, but not with obesity, triglycerides
or cholesterol levels (Table 3).
Kidney macrophages increase with diabetic
renal injury and fibrosis
Increased glomerular macrophage accumulation in di-
abetic db/db mice coincided with the onset and progres-
sion of glomerular damage (hypertrophy, hypercellular-
ity, sclerosis) and increased glomerular deposition of IgG
and C3 at 6 to 8 months (Table 4) (Figs. 3 and 4). Similarly,
increased numbers of interstitial macrophages surround-
ing cortical tubules, vessels and Bowman’s capsule, were
identified at 6 to 8 months, coinciding with a marked in-
crease in albuminuria and plasma creatinine, detection
of tubular injury (tubular dilatation, atrophy, apoptosis)
and the start of interstitial fibrosis (increased interstitial
volume, collagen IV deposition) (Table 4) (Fig. 3).
In diabetic db/db mice, glomerular macrophage accu-
mulation correlated with albuminuria, glomerular depo-
sition of IgG and C3, glomerular hypertrophy, glomerular
hypercellularity, glomerular matrix fraction, and
glomerular collagen IV, but not with plasma creatinine
(Table 5). Interstitial macrophages correlated with
albuminuria, plasma creatinine, tubular atrophy, tubular
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Fig. 3. Macrophage association with renal damage in diabetic db/db kidneys. Histologic staining with periodic acid-Schiff (PAS) reagent and
hematoxylin shows the normal structure of (A) a db/+ kidney at 8 months of age. In comparison, there is significant glomerular damage (hypertrophy,
hypercellularity and glomerulosclerosis), tubular injury (dilatation, atrophy), and interstitial infiltrate in (B) a diabetic db/db kidney at the same age.
Immunostaining shows only a few macrophages (brown) in a db/+ kidney at 8 months of age (C), and many glomerular and interstitial macrophages
in a diabetic db/db kidney at 8 months (D). Two-color immunostaining shows that some macrophages (brown) in diabetic kidneys (E) express
inducible nitric oxide synthase (iNOS) (blue), indicating their potential for causing renal injury (arrows). In addition, there are macrophages
(brown) in diabetic kidneys (F), which express proliferating cell nuclear antigen (PCNA) (blue), demonstrating that there is local macrophage
proliferation (arrow) (magnification A to D × 250; E and F × 1000).
apoptosis, interstitial volume, and interstitial collagen
IV (Table 5).
Glomerular and interstitial macrophages in diabetic
kidneys were frequently found to be proliferating
(PCNA+) or activated (iNOS+) (Fig. 3), and their num-
bers increased with progressive macrophage accumu-
lation. The proportion of glomerular and interstitial
macrophages expressing iNOS was two- to fourfold
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Fig. 4. Glomerular deposition of IgG and C3 in diabetic db/db kidneys. Immunofluorescence staining of 8-month-old mice identified weak glomeru-
lar staining for IgG in a normal db/+ kidney (A) and a nondiabetic db/db kidney (B), which increased markedly in a diabetic db/db kidney (C).
Similarly, the glomerular deposition of C3 was weakly detectable in a normal db/+ kidney (D) and a nondiabetic db/db kidney (E), but was
significantly greater in a db/db kidney (F) (magnification × 400).
greater in diabetic db/db compared to db/+ kidneys
(Table 4). An increase in the percentage of macrophages
expressing iNOS was first detected in glomeruli at the
onset of diabetes (2 months) and then later in the in-
terstitium (4 months). In contrast, the proportion of
macrophages expressing PCNA was smaller and did
not significantly change in diabetic compared to normal
kidneys.
Increased expression of macrophage chemokines
in type 2 diabetic nephropathy
At 8 months of age, diabetic db/db mice have increased
numbers of glomerular cells and cortical tubules express-
ing mRNA for MCP-1, osteopontin, MIF, and M-CSF
compared to age-matched, normal db/+ mice and 2-
month-old diabetic db/db mice (Fig. 5), indicating that
the up-regulation of these chemokines within the kidney
is dependent on the presence and duration of type 2 di-
abetes. A strong association between kidney chemokine
expression and prolonged hyperglycaemia was confirmed
by correlation analysis (Table 6). Glomerular chemokine
expression also correlated with glomerular deposition of
IgG and C3 (Table 6). Chemokine expression appeared
in both damaged tubules and glomeruli in diabetic
kidneys (Figs. 6 and 7). Within glomeruli, expression
appeared to be predominantly localized in podocytes
(Fig. 7) and occasionally seen in mesangial cells (not
shown). Although a similar staining pattern was seen for
each chemokine, the mRNA detection proved to be spe-
cific in each case since there was no staining detected
in diabetic glomeruli or damaged tubules with our sense
control probes, which is consistent with previous stud-
ies [15]. Glomerular and interstitial macrophage accu-
mulation correlated with the expression of chemokines
seen in diabetic glomeruli and cortical tubules, respec-
tively (Table 6). However, only tubular osteopontin cor-
related with the increase in the proportion of activated
(iNOS+) interstitial macrophages in diabetic kidneys
(r = 0.60, P = 0.0054). In addition, proliferating glomeru-
lar macrophages correlated with glomerular M-CSF
expression (r = 0.66, P = 0.0013); however, the small
number of interstitial macrophages proliferating in dia-
betic kidneys did not correlate with tubular M-CSF ex-
pression (r = 0.12, P = 0.61).
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Table 5. Correlation of renal injury with kidney accumulation of
macrophages and the percentage of activated [inducible nitric oxide
synthase (iNOS+)] macrophages
Glomerular Interstitial
macrophages macrophages
Total % iNOS+ Total % iNOS+
Renal Dysfunction
Albuminuria 0.54 0.51 0.62 0.49
(0.002) (0.004) (0.0003) (0.0056)
Plasma 0.28 0.86 0.41 0.91
Creatinine (NS) (<0.0001) (0.023) (<0.0001)
Glomerular
Volume 0.71 0.48 — —
(<0.0001) (0.0072)
Cellularity 0.73 0.60 — —
(<0.0001) (0.0004)
IgG 0.76 0.63 — —
(<0.0001) (<0.0001)
C3 0.73 0.53 — —
(<0.0001) (0.0014)
Matrix fraction 0.63 0.56 — —
(0.0002) (0.0013)
Collagen IV 0.80 0.65 — —
(<0.0001) (0.0001)
Tubular
Atrophy — — 0.76 0.59
(<0.0001) (0.0005)
Apoptosis — — 0.75 0.33
(<0.0001) (NS)
Interstitial
Volume — — 0.52 0.43
(0.0030) (0.018)
Collagen IV — — 0.78 0.47
(<0.0001) (0.011)
Analysis was performed on a combined group of db/db mice from 2, 4, 6,
and 8 months. Data are r value based on Spearman’s coefficient for IgG and C3
and Pearson’s coefficient for all other correlations; (P value); NS is not significant.
DISCUSSION
Our study suggests that kidney macrophage accumula-
tion plays a pathologic role in the progression of type 2 di-
abetic nephropathy in db/db mice. Kidney macrophages
were found to increase with the duration of diabetes, the
severity of renal injury and loss of renal function, and
their accumulation in glomeruli and the interstitium cor-
related with progressive glomerular and tubular injury,
respectively.
Our population of db/db mice included animals rang-
ing from moderately obese mice with normal blood lipids
and hyperglycemia to severely obese mice with hyperlipi-
demia and normal blood glucose levels. Examination of
these mice allowed us to distinguish the importance of hy-
perglycemia and hyperlipidemia in the accumulation of
kidney macrophages and the development of renal injury
in this model. We found that kidney macrophages and re-
nal injury correlated significantly with blood glucose and
HbA1c levels, but not with obesity or blood lipids, sug-
gesting that prolonged hyperglycemia may be a critical
factor driving kidney macrophage accumulation and re-
nal damage in type 2 diabetes.
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Fig. 5. Quantitation of glomerular and tubular expression of
macrophage chemokines in diabetic db/db mice. In situ hybridization
was used to detect mRNA for monocyte chemoattractant protein-1
(MCP-1), migration inhibitory factor (MIF), osteopontin (OPN) and
monocyte-colony-stimulating factor (M-CSF) in (A) glomerular cells
and (B) cortical tubules in diabetic db/db mice at 2 and 8 months of
age and in normal db/+ mice at 8 months of age. Data are mean ± SD.
∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.0005.
Macrophages in diabetic kidneys were found in the
glomerular tuft and around dilated tubules, which were
sites shown to express macrophage chemokines, in-
dicating a potential mechanism by which prolonged
hyperglycemia can promote kidney macrophage accumu-
lation. In situ hybridisation identified marked increases
in glomerular and tubular expression of MCP-1, MIF, os-
teopontin, and M-CSF with the duration of diabetes in
db/db mice, which correlated with glomerular and inter-
stitial macrophage accumulation, respectively. Tubular
expression of MCP-1 has previously been demonstrated
in human diabetic kidneys [16] and tubular osteopon-
tin levels have been shown to correlate with interstitial
macrophages in streptozotocin-induced type 1 diabetic
nephropathy in rats [17]. Both MCP-1 and osteopon-
tin are known to be required for kidney macrophage
accumulation and renal injury in acute and chronic mod-
els of kidney disease [18–21]. In this study, we demon-
strated that tubular expression of MIF and M-CSF are
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Table 6. Correlation of renal chemokine expression with blood glucose, hemoglobin A1c (HbA1c), glomerular IgG and C3 deposition, kidney
accumulation of macrophages, and the percentage of activated [inducible nitric oxide synthase (iNOS+)] macrophages
Glomerular cells Cortical tubules
MCP-1 MIF OPN M-CSF MCP-1 MIF OPN M-CSF
Blood glucose 0.75 0.76 0.86 0.75 0.69 0.85 0.86 0.59
(0.0001) (0.0001) (<0.0001) (0.0001) (0.0009) (<0.0001) (<0.0001) (0.006)
HbA1c 0.63 0.63 0.63 0.74 0.58 0.61 0.58 0.21
(0.0030) (0.0031) (0.0029) (0.0002) (0.0074) (0.0046) (0.0072) (NS)
IgG 0.86 0.85 0.75 0.83 — — — —
(<0.0001) (<0.0001) (0.0002) (<0.0001)
C3 0.73 0.74 0.79 0.72 — — — —
(0.0003) (0.0002) (<0.0001) (0.0004)
Glom MØ 0.82 0.87 0.66 0.83 — — — —
(<0.0001) (<0.0001) (0.0014) (<0.0001)
% iNOS+ glom MØ 0.036 0.014 0.29 −0.046 — — — —
(NS) (NS) (NS) (NS)
int MØ — — — — 0.52 0.74 0.65 0.55
(0.018) (0.0002) (0.0020) (0.012)
% iNOS+ — — — — 0.34 0.25 0.60 0.094
int MØ (NS) (NS) (0.0054) (NS)
Abbreviations are: MCP-1, monocyte chemoattractant protein-1; MIF, migration inhibitory factor; OPN, osteopontin; M-CSF, monocyte-colony-stimulating factor;
MØ, macrophage; int, interstial; glom, glomerular; NS, not significant.
Analysis was performed on a combined group of animals, including normal db/+ mice at 8 months and db/db mice at 2 and 8 months. Data are r value based on
Spearman’s coefficient for IgG and C3 and Pearson’s coefficient for all other correlations; (P value).
also associated with kidney macrophage accumulation
in diabetic nephropathy. Although MIF and M-CSF
share the ability to influence macrophage migration and
activation, they have distinct differences of action on
macrophages compared to MCP-1 and osteopontin. MIF
inhibits macrophages migrating away from its source
and counter-regulates the immunosuppressive effects of
glucocorticoids [22, 23]. M-CSF, in addition to being a
macrophage chemoattractant, is the major factor respon-
sible for local macrophage proliferation at sites of renal
inflammation [24]. Kidney expression of MIF and M-CSF
are associated with the progression of human prolifera-
tive glomerulonephritis and have been shown to play a
pathologic role in animal models of renal disease [24–27].
Hence, this study has identified renal production of MIF
and M-CSF as two potential additional mechanisms of
macrophage accumulation in diabetic kidneys resulting
from prolonged hyperglycemia.
Immune complex formation in diabetic nephropathy
may also play a role in kidney macrophage accumula-
tion. Several studies examining renal biopsies have noted
glomerular immune complex deposition in human dia-
betic nephropathy; however, it is unsure whether these
findings are directly related to the diabetes or an addi-
tional insult [28, 29]. Previous work has also shown that
glomerular levels of IgG and C3 increase with the dura-
tion of diabetes in db/db mice [30]. In the current study,
we demonstrated that glomerular macrophages in dia-
betic db/db kidneys correlated with increased glomerular
deposition of IgG and C3, suggesting that glomerular im-
mune complexes may promote glomerular macrophage
accrual. Notably, age-matched db/db mice that did not
develop hyperglycemia showed no increase in glomeru-
lar IgG and C3 deposition compared to db/+ controls,
indicating that their glomerular levels are associated with
hyperglycemia rather than obesity or the genetic make-
up of these animals. This finding is consistent with studies
in streptozotocin-treated rats in which insulin treatment
or islet transplantation reduced glomerular immunocom-
plex deposition [31, 32]. Mesangial cells cultured in the
presence of IgG complexes produce increased amounts
of MCP-1 and M-CSF, a process that is dependent on
Fc receptor occupancy [33]. Furthermore, experimental
immune complex nephritis shows increased glomeru-
lar chemokine expression in association with glomeru-
lar macrophage accumulation [34]. Therefore, it is
possible that glomerular macrophage accumulation in di-
abetic db/db mice may be, in part, promoted by immune
complex–induced glomerular chemokine expression.
Most immunolocalization studies indicate that tubu-
lar epithelial cells are the major source of macrophage
chemokines during renal inflammation. Indeed, proin-
flammatory stimuli are very effective in promoting tubu-
lar epithelial cell production of macrophage chemokines
[35]. In contrast to glomeruli, we found no immune com-
plex deposition in the tubules of diabetic db/db kidneys.
Therefore, to understand whether chemokines promote
interstitial macrophage accumulation in diabetic kidneys,
it is important to determine how the diabetic milieu can
stimulate macrophage chemokine production by tubular
epithelial cells. Previous work has shown that glycated al-
bumin can induce MCP-1 production by cultured mesan-
gial cells [36], suggesting a role for MCP-1 in macrophage
recruitment in diabetic glomeruli. Since tubular epithe-
lial cells also possess receptors for advanced glycation
end products (AGEs) [37], it is feasible that AGEs, such
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Fig. 6. Increased tubular expression of macrophages chemokines in diabetic db/db mice. In situ hybridization detected little mRNA expression
(purple) of (A) osteopontin, (C) monocyte chemoattractant protein-1 (MCP-1), (E) migration inhibitory factor (MIF), and (G) monocyte-colony-
stimulating factor (M-CSF) in normal db/+ kidneys at 8 months of age. In comparison, dilated tubules in diabetic db/db kidneys at 8 months
frequently expressed mRNA for (B) osteopontin, (D) MCP-1, (F) MIF, and (H) M-CSF. No staining was detected in diabetic kidneys when sense
control probes were used (data not shown) (magnification A to H × 250).
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as glycated albumin, may also induce chemokine produc-
tion by tubular epithelial cells. However, in the complex
environment of diabetic kidneys it is difficult to ascertain
whether tubular chemokine production is the result of
direct or indirect action of the diabetic milieu on tubules.
The correlation of kidney macrophages with increased
albuminuria, plasma creatinine, and tissue damage sug-
gests a role for macrophage-mediated renal injury in dia-
betic nephropathy. Recent work, involving the adoptive
transfer of macrophages into leukocyte-depleted animals
has established that macrophages can induce glomeru-
lar injury, promoting proteinuria and mesangial prolif-
eration [38]. Furthermore, the ability of macrophages
to induce glomerular injury is enhanced if their activa-
tion status is increased by pretreatment with interferon-
gamma (IFN-c ) [39]. This finding is supported by in vitro
studies indicating that activated macrophages can pro-
mote renal cell death. Lipopolysaccharide stimulation of
bone marrow–derived macrophages results in the secre-
tion of substances known to induce apoptosis in cultured
mesangial and tubular epithelial cells [20, 40]. In-
deed, macrophages can produce a variety of substances
which can promote renal injury [nitric oxide, reac-
tive oxygen species, interleukin-1 (IL-1), tumor necro-
sis factor-a (TNF-a), metalloproteinases] [9], and in-
hibiting the action of some of these molecules in mod-
els of acute renal injury reduces kidney damage [41–
43]. In vitro studies have demonstrated that AGEs can
induce macrophage secretion of nitric oxide, reactive oxy-
gen species, and TNF-a [44–46], indicating that the di-
abetic milieu may promote macrophage-mediated kid-
ney damage. In addition, glomerular expression of iNOS
is associated with macrophage infiltration in rat im-
mune complex glomerulonephritis [47] and in vitro stud-
ies have shown that immune complexes can increase
nitric oxide production by macrophages in the pres-
ence of IFN-c [48], indicating that glomerular immune
complexes in diabetic nephropathy may also promote
macrophage activation. In diabetic db/db kidneys, we
noted an increase in the numbers and proportion of
macrophages expressing iNOS, suggesting that these kid-
ney macrophages were producing nitric oxide and po-
tentially causing tissue injury. Indeed, the percentage of
iNOS+ macrophages was threefold greater in glomeruli
compared to the interstitium, indicating that glomeru-
lar immune complex deposition may be responsible
Fig. 7. Glomerular expression of macrophages chemokines in
8-month-old diabetic db/db mice. In situ hybridization detected
podocytic-like cells expressing mRNA (arrows) for (A) osteopontin,
(B) monocyte chemoattractant protein-1 (MCP-1), (C) migration in-
hibitory factor (MIF), and (D) monocyte-colony-stimulating factor
(M-CSF) in the diabetic glomeruli of db/db mice at 8 months (mag-
nification A to D × 1000).
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for the increased activation of macrophages in diabetic
glomeruli.
In addition to causing injury, macrophage activation
may also promote renal fibrosis through the secretion
of fibroblast growth factor (FGF) and PDGF [49], profi-
brotic factors [IL-1, transforming growth factor-b (TGF-
b)] [50–52], and molecules that activate TGF-b (plasmin,
thrombospondin-1) [52, 53]. Macrophage accumulation
in diabetic db/db kidneys correlated with increases in
glomerular and interstitial volume and glomerular and
interstitial collagen IV deposition, showing an associa-
tion between macrophages and the progression of renal
fibrosis. Therefore, macrophages have multiple potential
mechanisms by which they can mediate the progression
of diabetic nephropathy.
CONCLUSION
This study suggests that prolonged hyperglycemia pro-
motes the accumulation of kidney macrophages, which
are associated with the progression of type 2 dia-
betic nephropathy. However, proof of a pathologic role
will require further experiments that selectively de-
plete macrophages during the progression of diabetic
nephropathy. If a pathologic role for macrophages is
proven, the selective targeting of macrophages may be-
come an additional therapeutic strategy for halting the
advancement of diabetic nephropathy.
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